Akèy › Sistèm Imunitè ak Twoub › Kalifòni › Baldwin Park
Etid klinik pou Sistèm Imunitè ak Twoub nan Baldwin Park, CA
5 etid pou Sistèm Imunitè ak Twoub ap chèche patisipan nan sit nan ak bò kote Baldwin Park (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- City of Hope, Duarte · 4 mi lwen
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- City of Hope Comprehensive Cancer Center, Duarte · 4 mi lwen
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- City of Hope, Duarte · 4 mi lwen
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- City of Hope, Duarte · 4 mi lwen
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Ap rekriteFaz 2
- City of Hope National Medical Center, Duarte · 4 mi lwen
Etid Sistèm Imunitè ak Twoub nan lòt vil
- Washington, DC13 etid
- New York City, NY12 etid
- Boston, MA10 etid
- Philadelphia, PA10 etid
- Portland, OR9 etid
- Atlanta, GA9 etid
- Houston, TX9 etid
- Chicago, IL8 etid
- Los Angeles, CA8 etid
- Cleveland, OH8 etid
- Seattle, WA6 etid
- Milwaukee, WI6 etid
Lòt etid nan Baldwin Park
- Kansè nan tete45 etid
- Leksemi mieloïd egi40 etid
- Kansè kolorektal38 etid
- Kansè Poumon ki pa ti selil36 etid
- Kansè (tout kalite)33 etid
- Kansè pwostat30 etid
- Kansè Metastatik30 etid
- Sendwòm myelodisplastik26 etid
- Kansè ovè25 etid
- Kansè poumon24 etid
- Myelom Miltip23 etid
- Kansè lestomak22 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.